Does Rallies show live market data for CAMP?

Rallies combines live market context with ticker research for CAMP, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.

CAMP (CAMP4 Therapeutics Corporation Common Stock) Stock Analysis

CAMP4 Therapeutics Corporation Common Stock (CAMP) is a publicly traded Healthcare sector company. As of May 21, 2026, CAMP trades at $4.50 with a market cap of $236.78M and a P/E ratio of -1.90. CAMP moved +8.80% today. Year to date, CAMP is -24.87%; over the trailing twelve months it is +101.79%. Its 52-week range spans $1.31 to $12.30. Analyst consensus is strong buy with an average price target of $8.60. Rallies surfaces CAMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest CAMP stock research?

CAMP4 Therapeutics Corporation Common Stock (CAMP) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CAMP moved +8.80% today. Analyst consensus is strong buy.

CAMP Key Metrics

Key financial metrics for CAMP
Metric	Value
Price	$4.50
Market Cap	$236.78M
P/E Ratio	-1.90
EPS	$-2.36
Dividend Yield	0.00%
52-Week High	$12.30
52-Week Low	$1.31
Volume	0
Avg Volume	0
Revenue (TTM)	$3.93M
Net Income	$-86.30M
Gross Margin	0.00%

Latest CAMP News

CAMP4 Therapeutics’ CMP-002 Increases Seizure Threshold, Reduces Severity in SYNGAP1 Model — May 14, 2026
CAMP4 Secures EMA Orphan Designation, Files CMP-002 Trial in Australia, $99M Cash Runway — May 7, 2026
CAMP4 Therapeutics Maps Thousands of Regulatory RNAs, Increases OTC Expression — Apr 28, 2026
CAMP4 Raises $97.5M, Wins $17.5M GSK Upfront, Plans H2 2026 Phase 1/2 for CMP-002 — Mar 5, 2026
CAMP4 Grants 8,000 Options at $3.85 Exercise Price with Four-Year Vesting — Feb 20, 2026

Recent CAMP Insider Trades

5AM Partners VI, LLC bought 2.94M (~$4.50M) on Sep 11, 2025.
Polaris Management Co. VII, L.L.C. bought 1.22M (~$1.87M) on Sep 11, 2025.
Polaris Management Co. VII, L.L.C. bought 85.47K (~$130.77K) on Sep 11, 2025.

CAMP Analyst Consensus

6 analysts cover CAMP: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.60.

Common questions about CAMP

What can I research for CAMP on Rallies?: CAMP4 Therapeutics Corporation Common Stock (CAMP) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. CAMP moved +8.80% today. Analyst consensus is strong buy.
Does Rallies show live market data for CAMP?: Rallies combines live market context with ticker research for CAMP, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.